Naveen Pemmaraju: Transfusions with rare antibody profiles during leukemia management
Naveen Pemmaraju, Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC), shared an article by Grace S. Park on X:
“Delighted to share our new report just out in PubMed.
Our multi-disciplinary focus on transfusions with rare antibody profiles during leukemia management led by Dr Grace Park and Dr. Hima Atluri, Guillermo Montalban-Bravo.”
Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report.
Authors: Grace S. Park, et al.
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023